PL2590954T3 - Bisarylowe pochodne (tio)morfoliny jako modulatory S1P - Google Patents

Bisarylowe pochodne (tio)morfoliny jako modulatory S1P

Info

Publication number
PL2590954T3
PL2590954T3 PL11733829.3T PL11733829T PL2590954T3 PL 2590954 T3 PL2590954 T3 PL 2590954T3 PL 11733829 T PL11733829 T PL 11733829T PL 2590954 T3 PL2590954 T3 PL 2590954T3
Authority
PL
Poland
Prior art keywords
bisaryl
thio
modulators
morpholine derivatives
morpholine
Prior art date
Application number
PL11733829.3T
Other languages
English (en)
Inventor
Bakker Wouter I. Iwema
Raymond Bronger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2590954T3 publication Critical patent/PL2590954T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11733829.3T 2010-07-09 2011-07-08 Bisarylowe pochodne (tio)morfoliny jako modulatory S1P PL2590954T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36278510P 2010-07-09 2010-07-09
EP10169108 2010-07-09
US201161452977P 2011-03-15 2011-03-15
EP11158269 2011-03-15

Publications (1)

Publication Number Publication Date
PL2590954T3 true PL2590954T3 (pl) 2016-09-30

Family

ID=44323383

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11733829.3T PL2590954T3 (pl) 2010-07-09 2011-07-08 Bisarylowe pochodne (tio)morfoliny jako modulatory S1P

Country Status (13)

Country Link
US (3) US9029371B2 (pl)
EP (1) EP2590954B1 (pl)
JP (1) JP5841593B2 (pl)
CN (1) CN103080096B (pl)
AR (1) AR082137A1 (pl)
CA (1) CA2804329C (pl)
DK (1) DK2590954T3 (pl)
ES (1) ES2570744T3 (pl)
MX (1) MX338605B (pl)
PL (1) PL2590954T3 (pl)
TW (1) TW201206893A (pl)
UY (1) UY33495A (pl)
WO (1) WO2012004375A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
TWI522361B (zh) * 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
ES2554843T3 (es) * 2012-01-12 2015-12-23 F. Hoffmann-La Roche Ag Derivados heterocíclicos como receptores asociados de trazas de amina (TAARs)
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-(2-芳基吗啉-4-基)乙酯作为制备抗抑郁药物的应用
TW202132311A (zh) 2019-10-31 2021-09-01 美商E 斯蓋普生物股份有限公司 S1p受體調節劑之固體形式

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069387A1 (ru) 1982-07-01 1985-11-30 Институт физико-органической химии и углехимии АН УССР Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием
GB2228432A (en) 1989-01-13 1990-08-29 Grayston Central Services Multi-role machine for heating and coating pipe welds.
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
JP2681589B2 (ja) 1992-12-28 1997-11-26 日揮株式会社 配管溶接継手の熱処理方法
JPH072848A (ja) 1993-04-23 1995-01-06 Sankyo Co Ltd モルホリンおよびチオモルホリン誘導体
GB9522845D0 (en) 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
JP3822680B2 (ja) 1996-08-30 2006-09-20 新日本製鐵株式会社 誘導加熱された接合部の冷却方法および冷却装置
JP4518587B2 (ja) * 1998-03-09 2010-08-04 興和創薬株式会社 2−フェニルモルホリン誘導体
US6720343B2 (en) 2000-04-21 2004-04-13 Shionogi & Co., Ltd. Oxadiazole derivatives having anticancer effects
FR2822727A1 (fr) 2001-04-03 2002-10-04 Gesal Ind Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement
JP3649223B2 (ja) 2003-01-08 2005-05-18 株式会社日立製作所 配管系の熱処理方法および熱処理装置
PL1631557T3 (pl) * 2003-06-12 2007-05-31 Btg Int Ltd Cykliczne hydroksyloaminy jako związki psychoaktywne
JP4861177B2 (ja) 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0409744D0 (en) 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
WO2005105763A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP4491334B2 (ja) 2004-12-01 2010-06-30 日立Geニュークリア・エナジー株式会社 配管の熱処理方法および装置
JP4599250B2 (ja) 2005-08-10 2010-12-15 株式会社東芝 高周波誘導加熱時外面温度制御方法および当該制御装置
JP2007063642A (ja) 2005-09-01 2007-03-15 Hitachi Ltd 残留応力改善方法と高周波誘導加熱用コイル
EP2562168B1 (en) 2006-02-28 2014-04-16 Dart Neuroscience (Cayman) Ltd Therapeutic piperazines as pde4 inhibitors
EP2049548A1 (en) 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
PE20080769A1 (es) 2006-09-08 2008-08-14 Novartis Ag Derivados de biaril-sulfonamida
WO2008079382A1 (en) 2006-12-21 2008-07-03 Abbott Laboratories Sphingosine-1 -phosphate receptor agonist and antagonist compounds
EP2109606A1 (en) * 2007-02-02 2009-10-21 Novartis Ag Chromene s1p1 receptor antagonist
AU2007227278B2 (en) 2007-03-21 2014-09-11 Epix Pharmaceuticals, Inc. SIP receptor modulating compounds and use thereof
EA200901389A1 (ru) * 2007-04-23 2010-04-30 Новартис Аг Производные фталазина и изохинолина с модулирующим действием на s1p рецепторы
WO2009084501A1 (ja) 2007-12-27 2009-07-09 Asahi Kasei Pharma Corporation スルタム誘導体
KR20100105789A (ko) 2008-01-30 2010-09-29 세파론, 인코포레이티드 히스타민-3(h3)수용체 리간드로서의 치환된 스피로사이클릭 피페리딘 유도체
MX2010008375A (es) 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
US20090321144A1 (en) 2008-06-30 2009-12-31 Wyble Kevin J Protecting an element from excessive surface wear by localized hardening
UY32858A (es) * 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
JP5894086B2 (ja) 2010-02-04 2016-03-23 ラボラトリオス・デル・ドクター・エステベ・ソシエテ・アノニム 4−[−2−[[5−メチル−1−(2−ナフタレニル)−1h−ピラゾール−3−イル]オキシ]エチル]モルホリン塩酸塩多形体および溶媒和物
CN101812058B (zh) 2010-04-13 2012-03-21 湖南大学 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用

Also Published As

Publication number Publication date
JP2013531003A (ja) 2013-08-01
TW201206893A (en) 2012-02-16
MX2013000361A (es) 2013-04-29
US20160151376A1 (en) 2016-06-02
US20150191457A1 (en) 2015-07-09
WO2012004375A1 (en) 2012-01-12
UY33495A (es) 2012-01-31
US20130203745A1 (en) 2013-08-08
US9227960B2 (en) 2016-01-05
CA2804329A1 (en) 2012-01-12
US9029371B2 (en) 2015-05-12
JP5841593B2 (ja) 2016-01-13
DK2590954T3 (en) 2016-05-02
EP2590954B1 (en) 2016-04-13
AR082137A1 (es) 2012-11-14
CN103080096B (zh) 2015-12-09
CN103080096A (zh) 2013-05-01
US9662337B2 (en) 2017-05-30
CA2804329C (en) 2019-05-14
EP2590954A1 (en) 2013-05-15
ES2570744T3 (es) 2016-05-20
MX338605B (es) 2016-04-22

Similar Documents

Publication Publication Date Title
IL254839A0 (en) s1p modulatory factors
HK1238627A1 (zh) 作為離子通道調節劑的稠合雜環化合物
ZA201201446B (en) (thio)morpholine derivatives as s1p modulators
IL231229A0 (en) New history of dihydroquinoline-2-one
HK1184153A1 (zh) 作為 調節劑的螺-哌啶衍生物
EP2739613A4 (en) flavonoid
EP2794880A4 (en) METHODS FOR MODULATING EXPRESSION OF METASTASIS-ASSOCIATED ADENOCARCINOMA TRANSCRIPT (MALAT-1)
HK1191653A1 (zh) -糖苷衍生物
SG11201401937YA (en) New aryl-quinoline derivatives
HK1179956A1 (zh) 作為 調節劑的稠合雜環衍生物
EP2717923A4 (en) METHODS FOR MODULATING KALLICREIN EXPRESSION (KLKB1)
ZA201306586B (en) Thynyl derivatives as positive allosteric modulators of the mglur5
PL2590954T3 (pl) Bisarylowe pochodne (tio)morfoliny jako modulatory S1P
EP2726153A4 (en) METHOD FOR MODULATING CALLIQUE (KLKB1) EXPRESSION
GB2489487B (en) Applicator for an endoscope
HK1196605A1 (zh) -氧代-哌啶基衍生物
LU91770B1 (en) Replacement plug
EP2682156A4 (en) ANATOMIC APPLICATOR FOR HEMORRHOIDS
AU2011900081A0 (en) Dtp
EP2681187A4 (en) METHOD FOR REDUCING ACYLOXY SULFIDE DERIVATIVES
AU2011901900A0 (en) Motivation Aid
GB201010698D0 (en) Split boot replacement